CASBF (CanSino Biologics) FCF Margin % : -75.16% (As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is CanSino Biologics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. CanSino Biologics's Free Cash Flow for the three months ended in Jun. 2024 was $-17.73 Mil. CanSino Biologics's Revenue for the three months ended in Jun. 2024 was $23.59 Mil. Therefore, CanSino Biologics's FCF Margin % for the quarter that ended in Jun. 2024 was -75.16%.

As of today, CanSino Biologics's current FCF Yield % is -6.03%.

The historical rank and industry rank for CanSino Biologics's FCF Margin % or its related term are showing as below:

CASBF' s FCF Margin % Range Over the Past 10 Years
Min: -25113.37 Med: -364.82 Max: 18.87
Current: -108.91

During the past 9 years, the highest FCF Margin % of CanSino Biologics was 18.87%. The lowest was -25113.37%. And the median was -364.82%.

CASBF's FCF Margin % is ranked worse than
91.22% of 980 companies
in the Drug Manufacturers industry
Industry Median: 0.87 vs CASBF: -108.91

CanSino Biologics FCF Margin % Historical Data

The historical data trend for CanSino Biologics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanSino Biologics FCF Margin % Chart

CanSino Biologics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-3,991.08

18.87

-287.34

-442.30

-75.94

CanSino Biologics Quarterly Data
	Dec16	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Dec24
FCF Margin %	Get a 7-Day Free Trial														-83.23	-96.26	-212.29	-75.16	-

Competitive Comparison of CanSino Biologics's FCF Margin %

For the Drug Manufacturers - Specialty & Generic subindustry, CanSino Biologics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CanSino Biologics's FCF Margin % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CanSino Biologics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where CanSino Biologics's FCF Margin % falls into.

Save Embed

;

Save Embed

;

CanSino Biologics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

CanSino Biologics's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-86.039	/	113.297
	=	-75.94 %

CanSino Biologics's FCF Margin for the quarter that ended in Jun. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2024 )	/	Revenue (Q: Jun. 2024 )
	=	-17.731	/	23.59
	=	-75.16 %

CanSino Biologics FCF Margin % Related Terms

Thank you for viewing the detailed overview of CanSino Biologics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

CanSino Biologics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (OTCPK:CASBF) » Definitions » FCF Margin %

Traded in Other Exchanges

06185:Hong Kong CJH:Germany 688185:China

Address

185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN

Website

https://www.cansinotech.com

CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. Its products are Menhycia and Menphecia; Convidecia, Convidecia Air, and XBB.1.5 Variant; Ad5-EBOV; PCV13i; PBPV; and DTcP Infant. Its geographic areas are PRC and Overseas. It generates the majority of its revenue from the PRC.